Hos alle patienter, der behandles med abacavir, skal den kliniske mistanke om overfølsomhed danne grundlag for beslutning om behandlingen.
In any patient treated with abacavir, the clinical diagnosis of suspected hypersensitivity reaction must remain the basis of clinical decision-making.